Survivin and YM155: How faithful is the liaison?

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1845, Issue 2, 2014, Pages 202-220

  Rauch, Anke ^a   Hennig, Dorle ^a   Schäfer, Claudia ^a   Wirth, Matthias ^b   Marx, Christian ^a   Heinzel, Thorsten ^a   Schneider, Günter ^b   Krämer, Oliver H ^c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Cancer; Chemotherapy; Molecular target; Specificity; Survivin; YM155

Indexed keywords

CANCER; CHEMOTHERAPY; MOLECULAR TARGET; SPECIFICITY; SURVIVIN; YM155;

ANIMALS; APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; MICE; NAPHTHOQUINONES; NEOPLASMS; PROMOTER REGIONS, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893916874     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.01.003     Document Type: Review

References (223)

1. Altieri D.C. Targeting survivin in cancer. Cancer Lett. 2013, 332(2):225-228.
2. Sah N.K., Khan Z., Khan G.J., Bisen P.S. Structural, functional and therapeutic biology of survivin. Cancer Lett. 2006, 244:164-171.
3. Altieri D.C. Survivin and IAP proteins in cell-death mechanisms. Biochem. J. 2010, 430:199-205.
4. Knauer S.K., Mann W., Stauber R.H. Survivin's dual role: an export's view. Cell Cycle 2007, 6:518-521.
5. Castedo M., Perfettini J.L., Roumier T., Andreau K., Medema R., Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004, 23:2825-2837.
6. Wheatley S.P., McNeish I.A. Survivin: a protein with dual roles in mitosis and apoptosis. Int. Rev. Cytol. 2005, 247:35-88.
7. Church D.N., Talbot D.C. Survivin in solid tumors: rationale for development of inhibitors. Curr. Oncol. Rep. 2012, 14:120-128.
8. Rödel F., Sprenger T., Kaina B., Liersch T., Rodel C., Fulda S., Hehlgans S. Survivin as a prognostic/predictive marker and molecular target in cancer therapy. Curr. Med. Chem. 2012, 19:3679-3688.
9. Lladser A., Sanhueza C., Kiessling R., Quest A.F. Is survivin the potential Achilles' heel of cancer?. Adv. Cancer Res. 2011, 111:1-37.
10. Ryan B.M., O'Donovan N., Duffy M.J. Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 2009, 35:553-562.
11. Caldas H., Jiang Y., Holloway M.P., Fangusaro J., Mahotka C., Conway E.M., Altura R.A. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005, 24:1994-2007.
12. Knauer S.K., Bier C., Schlag P., Fritzmann J., Dietmaier W., Rödel F., Klein-Hitpass L., Kovács A.F., Döring C., Hansmann M.L., Hofmann W.K., Kunkel M., Brochhausen C., Engels K., Lippert B.M., Mann W., Stauber R.H. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 2007, 6:1502-1509.
13. Span P.N., Tjan-Heijnen V.C., Heuvel J.J., de Kok J.B., Foekens J.A., Sweep F.C. Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?. Clin. Chem. 2006, 52:1693-1700.
14. Végran F., Boidot R., Bonnetain F., Cadouot M., Chevrier S., Lizard-Nacol S. Apoptosis gene signature of survivin and its splice variant expression in breast carcinoma. Endocr. Relat. Cancer 2011, 18:783-792.
15. Végran F., Boidot R., Oudin C., Defrain C., Rebucci M., Lizard-Nacol S. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 2007, 26:290-297.
16. O'Connor D.S., Grossman D., Plescia J., Li F., Zhang H., Villa A., Tognin S., Marchisio P.C., Altieri D.C. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:13103-13107.
17. Barrett R.M., Osborne T.P., Wheatley S.P. Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activity. Cell Cycle 2009, 8:278-283.
18. Surova O., Zhivotovsky B. Various modes of cell death induced by DNA damage. Oncogene 2013, 32(33):3789-3797.
19. Yamamoto H., Ngan C.Y., Monden M. Cancer cells survive with survivin. Cancer Sci. 2008, 99:1709-1714.
20. Riolo M.T., Cooper Z.A., Holloway M.P., Cheng Y., Bianchi C., Yakirevich E., Ma L., Chin Y.E., Altura R.A. Histone deacetylase 6 (HDAC6) deacetylates survivin for its nuclear export in breast cancer. J. Biol. Chem. 2012, 287:10885-10893.
21. Wang H., Holloway M.P., Ma L., Cooper Z.A., Riolo M., Samkari A., Elenitoba-Johnson K.S., Chin Y.E., Altura R.A. Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J. Biol. Chem. 2010, 285:36129-36137.
22. Arora V., Cheung H.H., Plenchette S., Micali O.C., Liston P., Korneluk R.G. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J. Biol. Chem. 2007, 282:26202-26209.
23. Cheung H.H., Plenchette S., Kern C.J., Mahoney D.J., Korneluk R.G. The RING domain of cIAP1 mediates the degradation of RING-bearing inhibitor of apoptosis proteins by distinct pathways. Mol. Biol. Cell 2008, 19:2729-2740.
24. Gu B., Zhu W.G. Surf the post-translational modification network of p53 regulation. Int. J. Biol. Sci. 2012, 8:672-684.
25. Schneider G., Krämer O.H. NFkappaB/p53 crosstalk - a promising new therapeutic target. Biochim. Biophys. Acta 2011, 1815:90-103.
26. Hoffman W.H., Biade S., Zilfou J.T., Chen J., Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 2002, 277:3247-3257.
27. Mirza A., McGuirk M., Hockenberry T.N., Wu Q., Ashar H., Black S., Wen S.F., Wang L., Kirschmeier P., Bishop W.R., Nielsen L.L., Pickett C.B., Liu S. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002, 21:2613-2622.
28. Schneider G., Henrich A., Greiner G., Wolf V., Lovas A., Wieczorek M., Wagner T., Reichardt S., von Werder A., Schmid R.M., Weih F., Heinzel T., Saur D., Krämer O.H. Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene 2010, 29:2795-2806.
29. Brandl A., Wagner T., Uhlig K.M., Knauer S.K., Stauber R.H., Melchior F., Schneider G., Heinzel T., Krämer O.H. Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress. J. Mol. Cell Biol. 2012, 4(5):284-293.
30. Frank A.K., Leu J.I., Zhou Y., Devarajan K., Nedelko T., Klein-Szanto A., Hollstein M., Murphy M.E. The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol. Cell. Biol. 2011, 31:1201-1213.
31. Wang R.H., Zheng Y., Kim H.S., Xu X., Cao L., Luhasen T., Lee M.H., Xiao C., Vassilopoulos A., Chen W., Gardner K., Man Y.G., Hung M.C., Finkel T., Deng C.X. Interplay among BRCA1, SIRT1, and survivin during BRCA1-associated tumorigenesis. Mol. Cell 2008, 32:11-20.
32. Estève P.O., Chin H.G., Pradhan S. Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1000-1005.
33. Xu R., Zhang P., Huang J., Ge S., Lu J., Qian G. Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem. Biophys. Res. Commun. 2007, 356:286-292.
34. Krämer O.H., Baus D., Knauer S.K., Stein S., Jager E., Stauber R.H., Grez M., Pfitzner E., Heinzel T. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev. 2006, 20:473-485.
35. Füllgrabe J., Kavanagh E., Joseph B. Histone onco-modifications. Oncogene 2011, 30:3391-3403.
36. Yun M., Wu J., Workman J.L., Li B. Readers of histone modifications. Cell Res. 2011, 21:564-578.
37. Estève P.O., Chin H.G., Pradhan S. Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J. Biol. Chem. 2007, 282:2615-2625.
38. Smallwood A., Estève P.O., Pradhan S., Carey M. Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes Dev. 2007, 21:1169-1178.
39. Hervouet E., Vallette F.M., Cartron P.F. Impact of the DNA methyltransferases expression on the methylation status of apoptosis-associated genes in glioblastoma multiforme. Cell Death Dis. 2010, 1:e8.
40. Kanwar J.R., Kamalapuram S.K., Kanwar R.K. Survivin signaling in clinical oncology: a multifaceted dragon. Med. Res. Rev. 2013, 33(4):765-789.
41. Aggarwal B.B., Kunnumakkara A.B., Harikumar K.B., Gupta S.R., Tharakan S.T., Koca C., Dey S., Sung B. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann. N. Y. Acad. Sci. 2009, 1171:59-76.
42. Guo Y., Xu F., Lu T., Duan Z., Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 2012, 38(7):904-910.
43. Clevers H., Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012, 149:1192-1205.
44. Whitfield J.F. Calcium, calcium-sensing receptor and colon cancer. Cancer Lett. 2009, 275:9-16.
45. Obexer P., Hagenbuchner J., Unterkircher T., Sachsenmaier N., Seifarth C., Bock G., Porto V., Geiger K., Ausserlechner M. Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis. Mol. Biol. Cell 2009, 20:2041-2048.
46. Hagenbuchner J., Kuznetsov A.V., Obexer P., Ausserlechner M.J. BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. Oncogene 2013, 32:4748-4757.
47. Hagenbuchner J., Ausserlechner M.J. Mitochondria and FOXO3: breath or die. Front. Physiol. 2013, 4:147.
48. Knauer S.K., Krämer O.H., Knösel T., Engels K., Rodel F., Kovács A.F., Dietmaier W., Klein-Hitpass L., Habtemichael N., Schweitzer A., Brieger J., Rödel C., Mann W., Petersen I., Heinzel T., Stauber R.H. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J. 2007, 21:207-216.
49. Pal Bhadra M., Ramaiah M.J., Reddy L.T., Krishnan A., Sncvl P., Babu S.K., Tiwari A.K., Rao M.J., Yadav J.S., Bhadra U. Plant HDAC inhibitor chrysin arrest cell growth and induce p21WAF-1 by altering chromatin of STAT response element in A375 cells. BMC Cancer 2012, 12:180.
50. Spange S., Wagner T., Heinzel T., Krämer O.H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 2009, 41:185-198.
51. Zhu S., Li Y., Zhao L., Hou P., Shangguan C., Yao R., Zhang W., Zhang Y., Tan J., Huang B., Lu J. TSA-induced JMJD2B downregulation is associated with cyclin B1-dependent survivin degradation and apoptosis in LNCap cells. J. Cell. Biochem. 2012, 113:2375-2382.
52. Jin J.S., Tsao T.Y., Sun P.C., Yu C.P., Tzao C. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin. Pathol. Oncol. Res. 2012, 18:713-720.
53. Hsu Y.F., Sheu J.R., Lin C.H., Yang D.S., Hsiao G., Ou G., Chiu P.T., Huang Y.H., Kuo W.H., Hsu M.J. Trichostatin A and sirtinol suppressed survivin expression through AMPK and p38MAPK in HT29 colon cancer cells. Biochim. Biophys. Acta 2012, 1820:104-115.
54. Lachenmayer A., Toffanin S., Cabellos L., Alsinet C., Hoshida Y., Villanueva A., Minguez B., Tsai H.W., Ward S.C., Thung S., Friedman S.L., Llovet J.M. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J. Hepatol. 2012, 56:1343-1350.
55. Krämer O.H. HDAC2: a critical factor in health and disease. Trends Pharmacol. Sci. 2009, 30:647-655.
56. Zhang L., Wang G., Wang L., Song C., Leng Y., Wang X., Kang J. VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin. Mol. Cell. Biochem. 2012, 361:39-45.
57. Yi J., Luo J. SIRT1 and p53, effect on cancer, senescence and beyond. Biochim. Biophys. Acta 2010, 1804:1684-1689.
58. Wieczorek M., Ginter T., Brand P., Heinzel T., Krämer O.H. Acetylation modulates the STAT signaling code. Cytokine Growth Factor Rev. 2012, 23:293-305.
59. Okamoto H., Shiraki K., Yasuda R., Danjo K., Watanabe Y. Chitosan-interferon-beta gene complex powder for inhalation treatment of lung metastasis in mice. J. Control. Release 2011, 150:187-195.
60. Pollok S., Ginter T., Günzel K., Pieper J., Henke A., Stauber R.H., Reichardt W., Krämer O.H. Interferon alpha-armed nanoparticles trigger rapid and sustained STAT1-dependent anti-viral cellular responses. Cell. Signal. 2013, 25:989-998.
61. Coothankandaswamy V., Elangovan S., Singh N., Prasad P.D., Thangaraju M., Ganapathy V. The plasma membrane transporter SLC5A8 suppresses tumour progression through depletion of survivin without involving its transport function. Biochem. J. 2013, 450:169-178.
62. Thangaraju M., Gopal E., Martin P.M., Ananth S., Smith S.B., Prasad P.D., Sterneck E., Ganapathy V. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res. 2006, 66:11560-11564.
63. Thangaraju M., Carswell K.N., Prasad P.D., Ganapathy V. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem. J. 2009, 417:379-389.
64. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11:325-337.
65. Icard P., Lincet H. A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim. Biophys. Acta 2012, 1826:423-433.
66. Bradner J.E., Mak R., Tanguturi S.K., Mazitschek R., Haggarty S.J., Ross K., Chang C.Y., Bosco J., West N., Morse E., Lin K., Shen J.P., Kwiatkowski N.P., Gheldof N., Dekker J., DeAngelo D.J., Carr S.A., Schreiber S.L., Golub T.R., Ebert B.L. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:12617-12622.
67. Sehested J., Diernaes L., Møller P.D., Skadhauge E. Transport of butyrate across the isolated bovine rumen epithelium-interaction with sodium, chloride and bicarbonate. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 1999, 123:399-408.
68. Krämer O.H., Zhu P., Ostendorff H.P., Golebiewski M., Tiefenbach J., Peters M.A., Brill B., Groner B., Bach I., Heinzel T., Göttlicher M. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 2003, 22:3411-3420.
69. Zhang J., Kan S., Huang B., Hao Z., Mak T.W., Zhong Q. Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2. Genes Dev. 2011, 25:2610-2618.
70. Li F., Ackermann E.J., Bennett C.F., Rothermel A.L., Plescia J., Tognin S., Villa A., Marchisio P.C., Altieri D.C. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol. 1999, 1:461-466.
71. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584.
72. Baker S.J., Reddy E.P. CDK4: a key player in the cell cycle, development, and cancer. Genes Cancer 2012, 3:658-669.
73. Retzer-Lidl M., Schmid R.M., Schneider G. Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. Int. J. Cancer 2007, 121:66-75.
74. Raj D., Liu T., Samadashwily G., Li F., Grossman D. Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 2008, 29:194-201.
75. Jiang Y., Saavedra H.I., Holloway M.P., Leone G., Altura R.A. Aberrant regulation of survivin by the RB/E2F family of proteins. J. Biol. Chem. 2004, 279:40511-40520.
76. Suzuki A., Shiraki K. Tumor cell "dead or alive": caspase and survivin regulate cell death, cell cycle and cell survival. Histol. Histopathol. 2001, 16:583-593.
77. Suzuki A., Hayashida M., Ito T., Kawano H., Nakano T., Miura M., Akahane K., Shiraki K. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene 2000, 19:3225-3234.
78. Ito T., Shiraki K., Sugimoto K., Yamanaka T., Fujikawa K., Ito M., Takase K., Moriyama M., Kawano H., Hayashida M., Nakano T., Suzuki A. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000, 31:1080-1085.
79. Warfel N.A., El-Deiry W.S. p21WAF1 and tumourigenesis: 20years after. Curr. Opin. Oncol. 2013, 25:52-58.
80. Fukuda S., Mantel C.R., Pelus L.M. Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways. Blood 2004, 103:120-127.
81. Nakahara T., Takeuchi M., Kinoyama I., Minematsu T., Shirasuna K., Matsuhisa A., Kita A., Tominaga F., Yamanaka K., Kudoh M., Sasamata M. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007, 67:8014-8021.
82. Yamauchi T., Nakamura N., Hiramoto M., Yuri M., Yokota H., Naitou M., Takeuchi M., Yamanaka K., Kita A., Nakahara T., Kinoyama I., Matsuhisa A., Kaneko N., Koutoku H., Sasamata M., Kobori M., Katou M., Tawara S., Kawabata S., Furuichi K. Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. Biochem. Biophys. Res. Commun. 2012, 425:711-716.
83. Nakamura N., Yamauchi T., Hiramoto M., Yuri M., Naito M., Takeuchi M., Yamanaka K., Kita A., Nakahara T., Kinoyama I., Matsuhisa A., Kaneko N., Koutoku H., Sasamata M., Yokota H., Kawabata S., Furuichi K. ILF3/NF110 is a target of YM155, a suppressant of survivin. Mol. Cell. Proteomics 2012, 11(7). M111.013243.
84. Cheng Q., Ling X., Haller A., Nakahara T., Yamanaka K., Kita A., Koutoku H., Takeuchi M., Brattain M.G., Li F. Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int. J. Biochem. Mol. Biol. 2012, 3:179-197.
85. Grinstein E., Jundt F., Weinert I., Wernet P., Royer H.D. Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene 2002, 21:1485-1492.
86. Tolcher A.W., Mita A., Lewis L.D., Garrett C.R., Till E., Daud A.I., Patnaik A., Papadopoulos K., Takimoto C., Bartels P., Keating A., Antonia S. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J. Clin. Oncol. 2008, 26:5198-5203.
87. Iwai M., Minematsu T., Narikawa S., Usui T., Kamimura H. Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-napht ho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant. Drug Metab. Dispos. 2009, 37:1856-1863.
88. Aoyama Y., Nishimura T., Sawamoto T., Satoh T., Katashima M., Nakagawa K. Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment. Cancer Chemother. Pharmacol. 2012, 70:373-380.
89. Aoyama Y., Kaibara A., Takada A., Nishimura T., Katashima M., Sawamoto T. Population pharmacokinetic modeling of sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma. Invest. New Drugs 2013, 31:443-451.
90. Minematsu T., Iwai M., Sugimoto K., Shirai N., Nakahara T., Usui T., Kamimura H. Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-napht ho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells. Drug Metab. Dispos. 2009, 37:619-628.
91. Minematsu T., Iwai M., Umehara K., Usui T., Kamimura H. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab. Dispos. 2010, 38:1-4.
92. Iwai M., Minematsu T., Li Q., Iwatsubo T., Usui T. Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC-PK1 cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein. Drug Metab. Dispos. 2011, 39:2314-2320.
93. Lamers F., Schild L., Koster J., Versteeg R., Caron H.N., Molenaar J.J. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur. J. Cancer 2012, 48:763-771.
94. Risbridger G.P., Davis I.D., Birrell S.N., Tilley W.D. Breast and prostate cancer: more similar than different. Nat. Rev. Cancer 2010, 10:205-212.
95. Joshua A.M., Evans A., Van der Kwast T., Zielenska M., Meeker A.K., Chinnaiyan A., Squire J.A. Prostatic preneoplasia and beyond. Biochim. Biophys. Acta 2008, 1785:156-181.
96. Zumsteg Z.S., Zelefsky M.J. Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?. Lancet Oncol. 2012, 13:e259-e269.
97. van Bokhoven A., Varella-Garcia M., Korch C., Hessels D., Miller G.J. Widely used prostate carcinoma cell lines share common origins. Prostate 2001, 47:36-51.
98. Murakami Y., Matsuya T., Kita A., Yamanaka K., Noda A., Mitsuoka K., Nakahara T., Miyoshi S., Nishimura S. Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model. Nucl. Med. Biol. 2013, 40:221-226.
99. Wang Q., Chen Z., Diao X., Huang S. Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells. Cancer Lett. 2011, 302:29-36.
100. Tyner J.W., Jemal A.M., Thayer M., Druker B.J., Chang B.H. Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia 2012, 26:623-632.
101. Baudis M., Prima V., Tung Y.H., Hunger S.P. ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A-HLF expression. Pediatr. Blood Cancer 2006, 47:757-764.
102. Okuya M., Kurosawa H., Kikuchi J., Furukawa Y., Matsui H., Aki D., Matsunaga T., Inukai T., Goto H., Altura R.A., Sugita K., Arisaka O., Look A.T., Inaba T. Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells. J. Biol. Chem. 2010, 285:1850-1860.
103. Bernasconi M., Ueda S., Krukowski P., Bornhauser B.C., Ladell K., Dorner M., Sigrist J.A., Campidelli C., Aslandogmus R., Alessi D., Berger C., Pileri S.A., Speck R.F., Nadal D. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases. Int. J. Cancer 2013, 133(10):2341-2350.
104. Chang C.C., Heller J.D., Kuo J., Huang R.C. Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:13239-13244.
105. Huang R.C., Chang C.C., Mold D. Survivin-dependent and -independent pathways and the induction of cancer cell death by tetra-O-methyl nordihydroguaiaretic acid. Semin. Oncol. 2006, 33:479-485.
106. Sun Y., Giacalone N.J., Lu B. Terameprocol (tetra-O-methyl nordihydroguaiaretic acid), an inhibitor of Sp1-mediated survivin transcription, induces radiosensitization in non-small cell lung carcinoma. J. Thorac. Oncol. 2011, 6:8-14.
107. Leung C.G., Xu Y., Mularski B., Liu H., Gurbuxani S., Crispino J.D. Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J. Exp. Med. 2007, 204:1603-1611.
108. Gallo R.C. Research and discovery of the first human cancer virus, HTLV-1. Best Pract. Res. Clin. Haematol. 2011, 24:559-565.
109. Chen J., Pise-Masison C.A., Shih J.H., Morris J.C., Janik J.E., Conlon K.C., Keating A., Waldmann T.A. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. Blood 2013, 121:2029-2037.
110. Mori N., Yamada Y., Hata T., Ikeda S., Yamasaki Y., Tomonaga M., Yamamoto N. Expression of survivin in HTLV-I-infected T-cell lines and primary ATL cells. Biochem. Biophys. Res. Commun. 2001, 282:1110-1113.
111. Jiang L., Yuan C.M., Hubacheck J., Janik J.E., Wilson W., Morris J.C., Jasper G.A., Stetler-Stevenson M. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br. J. Haematol. 2009, 145:173-179.
112. Kawakami H., Tomita M., Matsuda T., Ohta T., Tanaka Y., Fujii M., Hatano M., Tokuhisa T., Mori N. Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int. J. Cancer 2005, 115:967-974.
113. Banerjee P., Sieburg M., Samuelson E., Feuer G. Human T-cell lymphotropic virus type 1 infection of CD34+ hematopoietic progenitor cells induces cell cycle arrest by modulation of p21(cip1/waf1) and survivin. Stem Cells 2008, 26:3047-3058.
114. Jeong S.J., Radonovich M., Brady J.N., Pise-Masison C.A. HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity. Blood 2004, 104:1490-1497.
115. Ng S.B., Selvarajan V., Huang G., Zhou J., Feldman A.L., Law M., Kwong Y.L., Shimizu N., Kagami Y., Aozasa K., Salto-Tellez M., Chng W.J. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J. Pathol. 2011, 223:496-510.
116. Kita A., Nakahara T., Yamanaka K., Nakano K., Nakata M., Mori M., Kaneko N., Koutoku H., Izumisawa N., Sasamata M. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk. Res. 2011, 35:787-792.
117. Kita A., Mitsuoka K., Kaneko N., Nakata M., Yamanaka K., Jitsuoka M., Miyoshi S., Noda A., Mori M., Nakahara T., Sasamata M. Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab. J. Pharmacol. Exp. Ther. 2012, 343:178-183.
118. Gupta M., Han J.J., Stenson M., Wellik L., Witzig T.E. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 2012, 26:1356-1364.
119. Kaneko N., Kita A., Yamanaka K., Mori M. Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma. Leuk. Res. 2013, 37(9):1156-1161.
120. Caceres-Cortes J.R. A potent anti-carcinoma and anti-acute myeloblastic leukemia agent, AG490. Anticancer Agents Med Chem. 2008, 8:717-722.
121. Song H., Wang R., Wang S., Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:4700-4705.
122. Krämer O.H., Knauer S.K., Greiner G., Jandt E., Reichardt S., Gührs K.H., Stauber R.H., Böhmer F.D., Heinzel T. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev. 2009, 23:223-235.
123. Marotta L.L., Polyak K. Unraveling the complexity of basal-like breast cancer. Oncotarget 2011, 2:588-589.
124. Crown J., O'Shaughnessy J., Gullo G. Emerging targeted therapies in triple-negative breast cancer. Ann. Oncol. 2012, 23(Suppl. 6):vi56-vi65.
125. Song J., Su H., Zhou Y.Y., Guo L.L. Prognostic value of survivin expression in breast cancer patients: a meta-analysis. Tumour Biol. 2013, 34:2053-2062.
126. Yamanaka K., Nakata M., Kaneko N., Fushiki H., Kita A., Nakahara T., Koutoku H., Sasamata M. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. Int. J. Oncol. 2011, 39:569-575.
127. Nakahara T., Kita A., Yamanaka K., Mori M., Amino N., Takeuchi M., Tominaga F., Kinoyama I., Matsuhisa A., Kudou M., Sasamata M. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 2011, 102:614-621.
128. Polyak K. Breast cancer gene discovery. Expert Rev. Mol. Med. 2002, 4:1-18.
129. Dallaglio K., Marconi A., Pincelli C. Survivin: a dual player in healthy and diseased skin. J. Invest. Dermatol. 2012, 132:18-27.
130. McKenzie J.A., Grossman D. Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer Res 2012, 32:397-404.
131. Yamanaka K., Nakahara T., Yamauchi T., Kita A., Takeuchi M., Kiyonaga F., Kaneko N., Sasamata M. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin. Cancer Res. 2011, 17:5423-5431.
132. Erovic I., Erovic B.M. Merkel cell carcinoma: the past, the present, and the future. J. Skin Cancer 2013, 2013:929364.
133. Miller N.J., Bhatia S., Parvathaneni U., Iyer J.G., Nghiem P. Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. Curr. Treat. Options Oncol. 2013, 14:249-263.
134. Arora R., Shuda M., Guastafierro A., Feng H., Toptan T., Tolstov Y., Normolle D., Vollmer L.L., Vogt A., Domling A., Brodsky J.L., Chang Y., Moore P.S. Survivin is a therapeutic target in merkel cell carcinoma. Sci. Transl. Med. 2012, 4:133ra156.
135. Schrama D., Hesbacher S., Becker J.C., Houben R. Survivin downregulation is not required for T antigen knockdown mediated cell growth inhibition in MCV infected merkel cell carcinoma cells. Int. J. Cancer 2013, 132:2980-2982.
136. Lamers F., van der Ploeg I., Schild L., Ebus M.E., Koster J., Hansen B.R., Koch T., Versteeg R., Caron H.N., Molenaar J.J. Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocr. Relat. Cancer 2011, 18:657-668.
137. Lima F.R., Kahn S.A., Soletti R.C., Biasoli D., Alves T., da Fonseca A.C., Garcia C., Romao L., Brito J., Holanda-Afonso R., Faria J., Borges H., Moura-Neto V. Glioblastoma: therapeutic challenges, what lies ahead. Biochim. Biophys. Acta 2012, 1826:338-349.
138. Lai P.C., Chen S.H., Yang S.H., Cheng C.C., Chiu T.H., Huang Y.T. Novel survivin inhibitor YM155 elicits cytotoxicity in glioblastoma cell lines with normal or deficiency DNA-dependent protein kinase activity. Pediatr. Neonatol. 2012, 53:199-204.
139. Lanvin O., Monferran S., Delmas C., Couderc B., Toulas C., Cohen-Jonathan-Moyal E. Radiation-induced mitotic cell death and glioblastoma radioresistance: A new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1alpha and survivin in U87 cells. Eur. J. Cancer 2013, 49(13):2884-2891.
140. Anderson C.W., Allalunis-Turner M.J. Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8. Radiat. Res. 2000, 154:473-476.
141. Virsik-Köpp P., Rave-Fränk M., Hofman-Hüther H., Schmidberger H. Role of DNA-PK in the process of aberration formation as studied in irradiated human glioblastoma cell lines M059K and M059J. Int. J. Radiat. Biol. 2003, 79:61-68.
142. Christmann M., Kaina B. Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation. Nucleic Acids Res. 2013, 41:8403-8420.
143. Collis S.J., DeWeese T.L., Jeggo P.A., Parker A.R. The life and death of DNA-PK. Oncogene 2005, 24:949-961.
144. Lin L.-H., Chan H.-L., Chou H.-C. DNA-dependent protein kinase regulated glioblastoma survival in doxorubicin-induced cytotoxicity. Genomic Med. Biomark. Health Sci. 2012, 4:54-56.
145. Kumar B., Yadav A., Lang J.C., Cipolla M., Schmitt A.C., Arradaza N., Teknos T.N., Kumar P. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels. Mol. Cancer Ther. 2012, 11(9):1988-1998.
146. Poh Y.W., Gan S.Y., Tan E.L. Effects of IL-6, IL-10 and TGF-beta on the expression of survivin and apoptosis in nasopharyngeal carcinoma TW01 cells. Exp. Oncol. 2012, 34:85-89.
147. Guo L., Tang M., Yang L., Xiao L., Bode A.M., Li L., Dong Z., Cao Y. Epstein-Barr virus oncoprotein LMP1 mediates survivin upregulation by p53 contributing to G1/S cell cycle progression in nasopharyngeal carcinoma. Int. J. Mol. Med. 2012, 29:574-580.
148. Bauman J.E., Austin M.C., Schmidt R., Kurland B.F., Vaezi A., Hayes D.N., Mendez E., Parvathaneni U., Chai X., Sampath S., Martins R.G. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br. J. Cancer 2013, 109:2096-2105.
149. Katz D., Lazar A., Lev D. Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev. Mol. Med. 2009, 11:e30.
150. Lee S.J., Park H.J., Kim Y.H., Kim B.Y., Jin H.S., Kim H.J., Han J.H., Yim H., Jeong S.Y. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells. Int. J. Mol. Med. 2012, 30:443-450.
151. Ghadimi M.P., Young E.D., Belousov R., Zhang Y., Lopez G., Lusby K., Kivlin C., Demicco E.G., Creighton C.J., Lazar A.J., Pollock R.E., Lev D. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors. Clin. Cancer Res. 2012, 18:2545-2557.
152. Hingorani P., Dickman P., Garcia-Filion P., White-Collins A., Kolb E.A., Azorsa D.O. BIRC5 expression is a poor prognostic marker in Ewing sarcoma. Pediatr. Blood Cancer 2013, 60:35-40.
153. Potratz J., Dirksen U., Jürgens H., Craft A. Ewing sarcoma: clinical state-of-the-art. Pediatr. Hematol. Oncol. 2012, 29:1-11.
154. Karosas A.O. Ewing's sarcoma. Am. J. Health Syst. Pharm. 2010, 67:1599-1605.
155. Sonnemann J., Palani C.D., Wittig S., Becker S., Eichhorn F., Voigt A., Beck J.F. Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells. Eur. J. Cancer 2011, 47:1432-1441.
156. Cao H., Le D., Yang L.X. Current status in chemotherapy for advanced pancreatic adenocarcinoma. Anticancer Res 2013, 33:1785-1791.
157. Yoon D.H., Shin J.S., Jin D.H., Hong S.W., Jung K.A., Kim S.M., Hong Y.S., Kim K.P., Lee J.L., Suh C., Lee J.S., Kim T.W. The survivin suppressant YM155 potentiates chemosensitivity to Gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. Anticancer Res 2012, 32:1681-1688.
158. Ye C.P., Qiu C.Z., Huang Z.X., Su Q.C., Zhuang W., Wu R.L., Li X.F. Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma. World J. Gastroenterol. 2007, 13:6264-6268.
159. Charette N., De Saeger C., Horsmans Y., Leclercq I., Starkel P. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms. Cell Death Dis. 2013, 4:e471.
160. Zhao X., Ogunwobi O.O., Liu C. Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells. PLoS One 2011, 6:e21980.
161. Min L., Ji Y., Bakiri L., Qiu Z., Cen J., Chen X., Chen L., Scheuch H., Zheng H., Qin L., Zatloukal K., Hui L., Wagner E.F. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat. Cell Biol. 2012, 14:1203-1211.
162. Hartkamp J., Roberts S.G. HtrA2, taming the oncogenic activities of WT1. Cell Cycle 2010, 9:2508-2514.
163. Tao Y.F., Lu J., Du X.J., Sun L.C., Zhao X., Peng L., Cao L., Xiao P.F., Pang L., Wu D., Wang N., Feng X., Li Y.H., Ni J., Wang J., Pan J. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC Cancer 2012, 12:619.
164. Akhtar M., Gallagher L., Rohan S. Survivin: role in diagnosis, prognosis, and treatment of bladder cancer. Adv Anat Pathol 2006, 13:122-126.
165. Custodio A., Mendez M., Provencio M. Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat. Rev. 2012, 38:36-53.
166. Travis W.D., Brambilla E., Müller-Hermelink H.K., Harris C.C. Pathology and genetics tumors of the lung, pleura, thymus and heart. World Health Organisation Classification of Tumours 2004, 341. World Health Organisation.
167. Langer C.J., Mok T., Postmus P.E. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treat. Rev. 2013, 39(3):252-260.
168. Petersen I. The morphological and molecular diagnosis of lung cancer. Dtsch. Arztebl. Int. 2011, 108:525-531.
169. Gompelmann D., Eberhardt R., Herth F.J. Advanced malignant lung disease: what the specialist can offer. Respiration 2011, 82:111-123.
170. Iwasa T., Okamoto I., Suzuki M., Nakahara T., Yamanaka K., Hatashita E., Yamada Y., Fukuoka M., Ono K., Nakagawa K. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin. Cancer Res. 2008, 14:6496-6504.
171. Iwasa T., Okamoto I., Takezawa K., Yamanaka K., Nakahara T., Kita A., Koutoku H., Sasamata M., Hatashita E., Yamada Y., Kuwata K., Fukuoka M., Nakagawa K. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br. J. Cancer 2010, 103:36-42.
172. Nakahara T., Yamanaka K., Hatakeyama S., Kita A., Takeuchi M., Kinoyama I., Matsuhisa A., Nakano K., Shishido T., Koutoku H., Sasamata M. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs 2011, 22:454-462.
173. Sun S., Schiller J.H., Gazdar A.F. Lung cancer in never smokers - a different disease. Nat. Rev. Cancer 2007, 7:778-790.
174. Gazdar A.F. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009, 28(Suppl. 1):S24-S31.
175. Tartarone A., Lazzari C., Lerose R., Conteduca V., Improta G., Zupa A., Bulotta A., Aieta M., Gregorc V. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer 2013, 81(3):328-336.
176. Okamoto K., Okamoto I., Hatashita E., Kuwata K., Yamaguchi H., Kita A., Yamanaka K., Ono M., Nakagawa K. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin. Mol. Cancer Ther. 2012, 11:204-213.
177. Okamoto K., Okamoto I., Okamoto W., Tanaka K., Takezawa K., Kuwata K., Yamaguchi H., Nishio K., Nakagawa K. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res. 2010, 70:10402-10410.
178. Roskoski R. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders. Expert Opin. Drug Discov. 2013, 8(9):1165-1179.
179. Lee S.O., Andey T., Jin U.H., Kim K., Singh M., Safe S. The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53. Oncogene 2012, 31:3265-3276.
180. Haruki N., Kawaguchi K.S., Eichenberger S., Massion P.P., Gonzalez A., Gazdar A.F., Minna J.D., Carbone D.P., Dang T.P. Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro. J. Med. Genet. 2005, 42:558-564.
181. Reynoird N., Schwartz B.E., Delvecchio M., Sadoul K., Meyers D., Mukherjee C., Caron C., Kimura H., Rousseaux S., Cole P.A., Panne D., French C.A., Khochbin S. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 2010, 29:2943-2952.
182. C.G.A.R.Network Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
183. Peifer M., Fernandez-Cuesta L., Sos M.L., George J., Seidel D., Kasper L.H., Plenker D., Leenders F., Sun R., Zander T., Menon R., Koker M., Dahmen I., Muller C., Di Cerbo V., Schildhaus H.U., Altmuller J., Baessmann I., Becker C., de Wilde B., Vandesompele J., Bohm D., Ansen S., Gabler F., Wilkening I., Heynck S., Heuckmann J.M., Lu X., Carter S.L., Cibulskis K., Banerji S., Getz G., Park K.S., Rauh D., Grutter C., Fischer M., Pasqualucci L., Wright G., Wainer Z., Russell P., Petersen I., Chen Y., Stoelben E., Ludwig C., Schnabel P., Hoffmann H., Muley T., Brockmann M., Engel-Riedel W., Muscarella L.A., Fazio V.M., Groen H., Timens W., Sietsma H., Thunnissen E., Smit E., Heideman D.A., Snijders P.J., Cappuzzo F., Ligorio C., Damiani S., Field J., Solberg S., Brustugun O.T., Lund-Iversen M., Sanger J., Clement J.H., Soltermann A., Moch H., Weder W., Solomon B., Soria J.C., Validire P., Besse B., Brambilla E., Brambilla C., Lantuejoul S., Lorimier P., Schneider P.M., Hallek M., Pao W., Meyerson M., Sage J., Shendure J., Schneider R., Buttner R., Wolf J., Nurnberg P., Perner S., Heukamp L.C., Brindle P.K., Haas S., Thomas R.K. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 2012, 44:1104-1110.
184. Blum B., Bar-Nur O., Golan-Lev T., Benvenisty N. The anti-apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells. Nat. Biotechnol. 2009, 27:281-287.
185. Lee M.O., Moon S.H., Jeong H.C., Yi J.Y., Lee T.H., Shim S.H., Rhee Y.H., Lee S.H., Oh S.J., Lee M.Y., Han M.J., Cho Y.S., Chung H.M., Kim K.S., Cha H.J. Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(35):E3281-E3290.
186. Shan B.E., Wang M.X., Li R.Q. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest. 2009, 27:604-612.
187. Kuo P.C., Liu H.F., Chao J.I. Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells. J. Biol. Chem. 2004, 279:55875-55885.
188. Polyak K., Hahn W.C. Roots and stems: stem cells in cancer. Nat. Med. 2006, 12:296-300.
189. Erba H.P., Sayar H., Juckett M., Lahn M., Andre V., Callies S., Schmidt S., Kadam S., Brandt J.T., Van Bockstaele D., Andreeff M. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest. New Drugs 2013, 31:1023-1034.
190. Miura K., Fujibuchi W., Ishida K., Naitoh T., Ogawa H., Ando T., Yazaki N., Watanabe K., Haneda S., Shibata C., Sasaki I. Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg. Today 2011, 41:175-182.
191. Kanwar R.K., Cheung C.H., Chang J.Y., Kanwar J.R. Recent advances in anti-survivin treatments for cancer. Curr. Med. Chem. 2010, 17:1509-1515.
192. Tracey L., Pérez-Rosado A., Artiga M.J., Camacho F.I., Rodriguez A., Martínez N., Ruiz-Ballesteros E., Mollejo M., Martinez B., Cuadros M., Garcia J.F., Lawler M., Piris M.A. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J. Pathol. 2005, 206:123-134.
193. Cheson B.D., Bartlett N.L., Vose J.M., Lopez-Hernandez A., Seiz A.L., Keating A.T., Shamsili S. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 2012, 118:3128-3134.
194. Satoh T., Okamoto I., Miyazaki M., Morinaga R., Tsuya A., Hasegawa Y., Terashima M., Ueda S., Fukuoka M., Ariyoshi Y., Saito T., Masuda N., Watanabe H., Taguchi T., Kakihara T., Aoyama Y., Hashimoto Y., Nakagawa K. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin. Cancer Res. 2009, 15:3872-3880.
195. Giaccone G., Zatloukal P., Roubec J., Floor K., Musil J., Kuta M., van Klaveren R.J., Chaudhary S., Gunther A., Shamsili S. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J. Clin. Oncol. 2009, 27:4481-4486.
196. Kelly R.J., Thomas A., Rajan A., Chun G., Lopez-Chavez A., Szabo E., Spencer S., Carter C.A., Guha U., Khozin S., Poondru S., Van Sant C., Keating A., Steinberg S.M., Figg W., Giaccone G. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol. 2013, 24(10):2601-2606.
197. Lewis K.D., Samlowski W., Ward J., Catlett J., Cranmer L., Kirkwood J., Lawson D., Whitman E., Gonzalez R. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest. New Drugs 2011, 29:161-166.
198. Tolcher A.W., Quinn D.I., Ferrari A., Ahmann F., Giaccone G., Drake T., Keating A., de Bono J.S. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann. Oncol. 2012, 23:968-973.
199. Balk S.P., Ko Y.J., Bubley G.J. Biology of prostate-specific antigen. J. Clin. Oncol. 2003, 21:383-391.
200. Tang H., Shao H., Yu C., Hou J. Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. Biochem. Pharmacol. 2011, 82:1066-1072.
201. Feng W., Yoshida A., Ueda T. YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells. Biochem. Biophys. Res. Commun. 2013, 435:52-57.
202. Na Y.S., Yang S.J., Kim S.M., Jung K.A., Moon J.H., Shin J.S., Yoon D.H., Hong Y.S., Ryu M.H., Lee J.L., Lee J.S., Kim T.W. YM155 induces EGFR suppression in pancreatic cancer cells. PLoS One 2012, 7:e38625.
203. Song Z., Yao X., Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J. Biol. Chem. 2003, 278:23130-23140.
204. Krämer O.H., Knauer S.K., Zimmermann D., Stauber R.H., Heinzel T. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 2008, 27:732-740.
205. Salehi F., Kovacs K., Scheithauer B.W., Lloyd R.V., Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr. Relat. Cancer 2008, 15:721-743.
206. Chao J.I., Liu H.F. The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells. Mol. Pharmacol. 2006, 69:154-164.
207. Glaros T.G., Stockwin L.H., Mullendore M.E., Smith B., Morrison B.L., Newton D.L. The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother. Pharmacol. 2012, 70:207-212.
208. Shoemaker R.H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 2006, 6:813-823.
209. Roos W.P., Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2013, 332:237-248.
210. Cann K.L., Dellaire G. Heterochromatin and the DNA damage response: the need to relax. Biochem. Cell Biol. 2011, 89:45-60.
211. Capalbo G., Rödel C., Stauber R.H., Knauer S.K., Bache M., Kappler M., Rödel F. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. Strahlenther. Onkol. 2007, 183:593-599.
212. Capalbo G., Dittmann K., Weiss C., Reichert S., Hausmann E., Rödel C., Rödel F. Radiation-induced survivin nuclear accumulation is linked to DNA damage repair. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77:226-234.
213. Holmes D. Cancer drug's survivin suppression called into question. Nat. Med. 2012, 18:842-843.
214. Reichert S., Rödel C., Mirsch J., Harter P.N., Tomicic M.T., Mittelbronn M., Kaina B., Rödel F. Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma. Radiother. Oncol. 2011, 101:51-58.
215. Ling X., Cao S., Cheng Q., Keefe J.T., Rustum Y.M., Li F. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS One 2012, 7:e45571.
216. Brown T.R., Vijarnsorn C., Potts J., Milner R., Sandor G.G., Fryer C. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study. Pediatr. Blood Cancer 2013, 60:842-848.
217. Qin H., Yu T., Qing T., Liu Y., Zhao Y., Cai J., Li J., Song Z., Qu X., Zhou P., Wu J., Ding M., Deng H. Regulation of apoptosis and differentiation by p53 in human embryonic stem cells. J. Biol. Chem. 2007, 282:5842-5852.
218. Smith A.J., Nelson N.G., Oommen S., Hartjes K.A., Folmes C.D., Terzic A., Nelson T.J. Apoptotic susceptibility to DNA damage of pluripotent stem cells facilitates pharmacologic purging of teratoma risk. Stem Cells Transl. Med. 2012, 1:709-718.
219. Yao Y.L., Yang W.M. Nuclear proteins: promising targets for cancer drugs. Curr. Cancer Drug Targets 2005, 5:595-610.
220. Yagata H., Kajiura Y., Yamauchi H. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer 2011, 18:165-173.
221. Mok T.S. Personalized medicine in lung cancer: what we need to know. Nat. Rev. Clin. Oncol. 2011, 8:661-668.
222. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 2012, 9:16-32.
223. Hansen J.B., Fisker N., Westergaard M., Kjaerulff L.S., Hansen H.F., Thrue C.A., Rosenbohm C., Wissenbach M., Orum H., Koch T. SPC3042: a proapoptotic survivin inhibitor. Mol. Cancer Ther. 2008, 7:2736-2745.